Outcomes of Critically Ill Pregnant Women with COVID-19 in the United States

To the Editor:

Data from viral respiratory illnesses such as influenza, severe acute respiratory syndrome coronavirus 1, and Middle East respiratory syndrome suggest that viral respiratory infection during pregnancy may worsen both maternal and fetal outcomes (1, 2). Existing data in critically ill pregnant women with coronavirus disease (COVID-19) are mainly limited to case series or systematic reviews lacking nonpregnant control subjects (3–5). To better understand this potentially at-risk population, we describe the clinical course of 32 critically ill pregnant women admitted to ICUs across the United States. Furthermore, we compare the characteristics, treatment, and outcomes of these pregnant women with those of women who were not pregnant at the time of ICU admission.

We used data from STOP-COVID (Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19), a multicenter cohort study of critically ill adults with laboratory-confirmed COVID-19 admitted to 67 participating ICUs across the United States (6). For the current analysis, we included all COVID-19–positive pregnant women admitted to ICUs between March 4 and May 2, 2020. We matched each pregnant woman with two nonpregnant women according to age (±2 yr) and the Quick Sequential Organ Failure Assessment (qSOFA) score at admission to the ICU (7). For purposes of matching, we dichotomized the qSOFA score into lower risk (score of 0–1) and higher risk (score of 2–3). All patients were followed up until hospital discharge, death, or a minimum of 28 days after ICU admission. We compared outcomes between pregnant and nonpregnant women using chi-square or Fisher exact tests for categorical variables and the Wilcoxon rank-sum test for continuous variables.

Among 4,145 patients in the parent cohort, we identified 32 pregnant women and matched these to 64 nonpregnant women. The median age in both groups was 32 years (interquartile range, 27–35). In both groups, 62.5% of patients had a qSOFA score of 2 or 3 at admission. The frequency and severity of acute respiratory failure, assessed by receipt of invasive mechanical ventilation and the \( \frac{P_{A\text{O}_2}}{F_{\text{I}O_2}} \) ratio at ICU admission, were similar between groups (Table 1).

Pregnant women were more likely to receive remdesivir (50.0% vs. 10.9%) and less likely to receive tocilizumab than nonpregnant women (9.4% vs. 23.4%). The rate of invasive mechanical ventilation, prone positioning, and neuromuscular blockade during the 14 days after ICU admission was similar between groups. The incidences of venous thromboembolism and other acute organ injuries, together with ICU and hospital length of stay, were similar between groups (Table 1). There were no maternal or fetal deaths, whereas 6 of the 64 nonpregnant women (9.4%) died during hospitalization.

A total of 19 women (59.3%) delivered during the hospitalization, with 11 of the 19 deliveries (57.9%) occurring on the day of ICU admission. Among the 19 deliveries, 18 (94.7%) were preterm, defined as occurring at less than 37 weeks’ gestation. Only three of these preterm births were spontaneous, with the remainder performed for medical or obstetric indications. The most common indications for delivery were maternal respiratory failure (52.6%), spontaneous labor or rupture of membranes (25.0%), and nonreassuring fetal status (21.1%) (Table 2). A total of 17 of the 19 women (89.5%) who delivered underwent cesarean section, with maternal critical illness reported as the most common indication (41.2%). Among the 17 women with pregnancies at more than 30 weeks’ gestation at ICU admission, 15 (88.2%) delivered, as compared with 4 out of 15 (26.7%) who delivered at less than 30-weeks’ gestation.

Unlike prior viral pandemics (1–4), maternal and fetal outcomes among critically ill pregnant women with COVID-19 in our cohort were excellent, with no reported deaths. Consistent with prior COVID-19 studies in pregnant women, our study found high rates of cesarean delivery and preterm birth (3–5). The majority of preterm delivery occurred in the setting of maternal respiratory failure, with a high rate of cesarean delivery for this indication. Complex medical decision-making is required in the management of critically ill pregnant women. The decision regarding delivery needs to balance multiple risks and benefits, including the risks of prematurity to the fetus, the potential to improve or worsen maternal respiratory status with delivery, and the known maternal hemodynamic and inflammatory burden accompanying major surgery such as cesarean section (8). Pregnant women in our cohort at less than 30-weeks’ gestation at the time of ICU admission were less likely to undergo delivery, which may reflect attempts to maximize fetal survival.

Pregnant women in our cohort had lower mortality than age- and qSOFA-matched nonpregnant women. This finding may reflect the lower burden of comorbidities among pregnant women in our small cohort. Notably, a recently published case series from Iran reported a high rate of mortality (77.8%) among nine critically ill pregnant women with COVID-19 (9). Potential reasons for the vastly different outcomes observed in the pregnant women in our cohort include differences in healthcare delivery systems, patient risk factors, and an apparently low threshold for ICU admission for pregnant patients with COVID-19 in our cohort. We followed patients until hospital discharge, but our cohort lacks long-term follow-up data, including neonatal outcomes. Both pregnancy and COVID-19 raise the risk of thromboembolic disease, highlighting the need for long-term follow-up data in pregnant and postpartum women with COVID-19.
Table 1. Characteristics, Therapies, and Outcomes according to Pregnancy Status

| Characteristic                                      | Pregnant (N = 32) | Nonpregnant (N = 64) | P Value |
|-----------------------------------------------------|-------------------|----------------------|---------|
| Age, yr, median (IQR)                               | 32 (27–35)        | 32 (27–35)           | 0.99    |
| qSOFA score at ICU admission                        | 0–1               | 12 (37.5)            | 0.99    |
|                                                     | 2–3               | 20 (62.5)            |         |
| Race, n (%)                                         |                   |                      | 0.49    |
| White                                               | 10 (31.2)         | 23 (35.9)            |         |
| Black                                               | 7 (21.9)          | 20 (31.2)            |         |
| Asian                                               | 3 (9.4)           | 4 (6.2)              |         |
| Hispanic ethnicity, n (%)                           | 9 (28.1)          | 20 (31.3)            | 0.75    |
| Body mass index, kg/m², median (IQR)*               | 33.7 (27.0–38.2)  | 38.7 (29.9–42.2)     | 0.10    |
| Coexisting conditions, n (%)                        |                   |                      |         |
| Diabetes mellitus                                   | 4 (12.5)          | 22 (34.4)            | 0.02    |
| Hypertension                                        | 3 (9.4)           | 16 (25.0)            | 0.07    |
| Asthma                                              | 9 (28.1)          | 16 (25.0)            | 0.74    |
| Chronic kidney disease                              | 1 (3.1)           | 2 (3.1)              | 0.99    |
| Time from symptom onset to ICU admission, d, median (IQR) | 7 (5–10) | NA                  | NA      |
| Vital signs on day of ICU admission, median (IQR)   |                   |                      |         |
| Temperature, °C                                      | 37.5 (37.0–38.0)  | 38.4 (37.3–39.3)     | <0.01   |
| Systolic blood pressure, mm Hg                      | 99 (91–110)       | 99 (89–106)          | 0.64    |
| Heart rate, beats/min                               | 116 (108–128)     | 119 (102–132)        | 0.81    |
| Respiratory rate, breaths/min                       | 28 (23–37)        | 34 (27–40)           | 0.02    |
| Laboratory findings on day of ICU admission, median (IQR)* |         |                      |         |
| White blood cell count, ×10⁶ cells/L                | 9.4 (7.8–12.7)    | 7.6 (5.3–11.1)       | 0.04    |
| Creatinine, mg/dl                                   | 0.5 (0.5–0.7)     | 0.7 (0.6–0.9)        | <0.01   |
| D-dimer, ng/ml                                      | 890 (640–1,374)   | 845 (441–1,888)      | 0.68    |
| C-reactive protein, mg/L                            | 99 (77–118)       | 119 (53–237)         | 0.27    |
| Invasive mechanical ventilation, n (%)              | 18 (56.2)         | 37 (57.8)            | 0.88    |
| PaO₂/FIO₂, mm Hg, median (IQR)*                     | 183 (108–261)     | 144 (100–230)        | 0.42    |
| Gestational age at ICU admission, wk, median (IQR)  | 30.4 (25.8–33.5)  | NA                   | NA      |
| Treatments and organ injury within the first 14 d of ICU admission |         |                      |         |
| Interventions for hypoxemia, n (%)                  |                   |                      |         |
| Prone position                                      | 11 (34.4)         | 25 (39.1)            | 0.65    |
| Neuromuscular blockade                              | 9 (28.1)          | 28 (43.8)            | 0.14    |
| Inhaled epoprostenol or nitric oxide                | 3 (9.4)           | 10 (15.6)            | 0.40    |
| Medical therapy, n (%)                              |                   |                      |         |
| Remdesivin                                          | 16 (50.0)         | 7 (10.9)             | <0.01   |
| Tocilizumab                                         | 3 (9.4)           | 15 (23.4)            | 0.10    |
| Convalescent plasma                                 | 4 (12.5)          | 6 (9.4)              | 0.73    |
| Any experimental therapy‡                           | 17 (53.1)         | 25 (39.1)            | 0.19    |
| Therapeutic anticoagulation                         | 13 (41.1)         | 28 (43.8)            | 0.77    |
| Acute respiratory distress syndrome, n (%)          | 16 (50.0)         | 16 (50)              | 0.03    |
| Invasive mechanical ventilation, n (%)              | 23 (71.9)         | 48 (75.0)            | 0.74    |
| Mechanical ventilation duration, d, median (IQR)‡   | 11 (6–14)         | 13 (8–14)            | 0.53    |
| Vasopressors, n (%)                                 | 23 (71.8)         | 23 (71.9)            | 0.23    |
| Acute kidney injury, n (%)                          | 4 (12.5)          | 15 (25.0)            | 0.16    |
| Renal replacement therapy, n (%)                    | 0 (0)             | 6 (10.0)             | 0.09    |
| Arrhythmia, n (%)                                   | 1 (3.1)           | 1 (1.6)              | 0.99    |
| Extracorporeal membrane oxygenation, n (%)         | 3 (9.4)           | 3 (4.7)              | 0.40    |
| Thrombosis, n (%)                                   | 2 (6.2)           | 7 (10.9)             | 0.71    |
| Outcomes                                           |                   |                      |         |
| In-hospital death, n (%)                            | 0 (0)             | 6 (9.4)              | 0.17    |
| ICU length of stay, d, median (IQR)§                | 10 (3–18)         | 13 (5–24)            | 0.28    |
| Hospital length of stay, d, median (IQR)§          | 14 (8–24)         | 11 (5–23)            | 0.13    |
| Delivered during hospitalization, n (%)§            | 19 (59.4)         | NA                   | NA      |
| Cesarean delivery, n (%)                            | 17 (53.1)         | NA                   | NA      |
| Gestational age at delivery, wk, median (IQR)       | 32.9 (30.1–34.4)  | NA                   | NA      |

Definition of abbreviations: IQR = interquartile range; NA = not applicable; qSOFA = Quick Sequential Organ Failure Assessment.

‡Experimental therapies were remdesivir, tocilizumab, and convalescent plasma.

§Acute kidney injury was defined as doubling of baseline creatinine or need for renal replacement therapy. Patients with end-stage renal disease (n = 4) were excluded.

¶Indications for delivery were maternal respiratory failure (n = 10), fetal status (n = 5), spontaneous labor or rupture of membranes (n = 3), and preeclampsia (n = 1).
Table 2. Case Details of Critically Ill Pregnant Patients with COVID-19

| Case* | Gestational Age at ICU Admission (wk) | Delivery during Admission | Days between Admission and Delivery | Gestational Age at Delivery (wk) | Mode of Delivery | Indication for Cesarean Delivery | Indication for Cesarean Delivery on Intubation | PaO2/FIO2 | Duration of Mechanical Ventilation† (d) | ICU Length of Stay† (d) | Hospital Length of Stay† (d) |
|-------|--------------------------------------|---------------------------|-------------------------------------|----------------------------------|------------------|---------------------------------|---------------------------------------------|----------|--------------------------------------|------------------------|-------------------------|
| 1     | ≥37                                  | Yes                       | <1                                 | 40.6                             | Vaginal          | Spontaneous labor              | NA                                          | 513      | 1                                    | 1                      | 5                      |
| 2     | 34.0–36.9                            | Yes                       | <1                                 | 36.4                             | Cesarean         | Respiratory failure            | Breech                                      | NA       | 0                                    | 5                      | 8                      |
| 3     | 34.0–36.9                            | Yes                       | ≥2                                 | 37.0                             | Cesarean         | Fetal status                  | Fetal heart rate                            | NA       | 0                                    | 1                      | 8                      |
| 4     | 34.0–36.9                            | Yes                       | ≤1                                 | 36.6                             | Cesarean         | Fetal status                  | Fetal heart rate                            | 268      | 6                                    | 7                      | 13                     |
| 5     | 34.0–36.9                            | Yes                       | 1–2                                | 34.4                             | Cesarean         | Respiratory failure            | Critical illness                            | 117      | 14                                   | 25                     | 35                     |
| 6     | 28.0–33.9                            | Yes                       | ≥2                                 | 34.4                             | Cesarean         | Preeclampsia                  | Critical illness                            | NA       | 0                                    | 1                      | 4                      |
| 7     | 28.0–33.9                            | Yes                       | ≤1                                 | 33.6                             | Cesarean         | Respiratory failure            | Labor                                       | NA       | 0                                    | 1                      | 6                      |
| 8     | 28.0–33.9                            | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | NA       | 0                                    | 1                      | 3                      |
| 9     | 28.0–33.9                            | Yes                       | ≤1                                 | 33.4                             | Cesarean         | Respiratory failure            | Critical illness                            | 101      | 5                                    | 6                      | 14                     |
| 10    | 28.0–33.9                            | Yes                       | ≥2                                 | 32.9                             | Cesarean         | Respiratory failure            | Breech                                      | 158      | 14                                   | 15                     | 24                     |
| 11    | 28.0–33.9                            | Yes                       | ≤1                                 | 31.6                             | Cesarean         | Respiratory failure            | Critical illness                            | 232      | 14                                   | 18                     | 22                     |
| 12    | 28.0–33.9                            | Yes                       | ≥2                                 | 32.7                             | Cesarean         | Respiratory failure            | Labor                                       | 184      | 6                                    | 14                     | 21                     |
| 13    | 28.0–33.9                            | Yes                       | ≤1                                 | 30.7                             | Cesarean         | Respiratory failure            | Critical illness                            | 62       | 14                                   | 25                     | 28                     |
| 14    | 28.0–33.9                            | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | NA       | 0                                    | 1                      | 7                      |
| 15    | 28.0–33.9                            | Yes                       | ≥2                                 | 31.4                             | Cesarean         | Respiratory failure            | Critical illness                            | 102      | 11                                   | 15                     | 18                     |
| 16    | 28.0–33.9                            | Yes                       | ≤1                                 | 30.1                             | Cesarean         | Respiratory failure            | Critical illness                            | 576      | 9                                    | 9                      | 13                     |
| 17    | 28.0–33.9                            | Yes                       | ≤1                                 | 29.4                             | Cesarean         | Respiratory failure            | Critical illness                            | 66       | 14                                   | 36                     | 44                     |
| 18    | 28.0–33.9                            | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | NA       | 0                                    | 3                      | 8                      |
| 19    | 24.0–27.9                            | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | NA       | 0                                    | 3                      | 23                     |
| 20    | 24.0–27.9                            | Yes                       | ≥2                                 | 30.0                             | Vaginal          | SROM and labor                | NA                                          | 161      | 14                                   | 29                     | 38                     |
| 22    | 24.0–27.9                            | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | 420      | 7                                    | 10                     | 23                     |
| 23    | 24.0–27.9                            | Yes                       | 1–2                                | 26.0                             | Cesarean         | Fetal status                  | Fetal heart rate                            | 92       | 10                                   | 12                     | 13                     |
| 24    | 24.0–27.9                            | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | NA       | 13                                   | 15                     | 21                     |
| 25    | 24.0–27.9                            | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | 254      | 6                                    | 8                      | 12                     |
| 26    | 24.0–27.9                            | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | 183      | 14                                   | 41                     | 61                     |
| 27    | 24.0–27.9                            | Yes                       | ≥2                                 | 26.1                             | Cesarean         | Fetal status                  | Fetal heart rate                            | 417      | 8                                    | 21                     | 38                     |
| 28    | 24.0–27.9                            | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | 348      | 7                                    | 10                     | 12                     |
| 29    | <24                                  | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | 197      | 1                                    | 1                      | 7                      |
| 30    | <24                                  | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | 252      | 13                                   | 19                     | 30                     |
| 31    | <24                                  | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | 310      | 13                                   | 19                     | 25                     |
| 32    | <24                                  | No                        | NA                                 | NA                               | NA               | NA                             | NA                                          | NA       | 0                                    | 2                      | 5                      |

Definition of abbreviations: COVID-19 = coronavirus disease; NA = not applicable; SROM = spontaneous rupture of membranes.

*Five patients were included as cases in References 4 and 5.

†The median ICU length of stay was 11 days (IQR, 6–22 d) for those without delivery versus 12 days (IQR, 5–21 d) for those who delivered during admission. The median hospital length of stay was 11 days (IQR, 6–22 d) for those without delivery versus 18 days (IQR, 8–28 d) for those who delivered during admission. The median duration of mechanical ventilation was 6 days (IQR, 0–13 d) for those without delivery versus 9 days (IQR, 1–14 d) for those who delivered during admission.
In summary, we report the maternal and fetal outcomes of 32 pregnant women in a multicenter cohort study of geographically diverse critically ill patients with COVID-19. In contrast to nonpregnant women of childbearing age, all pregnant women survived, and there were no fetal deaths. Treatments and outcomes, including receipt of invasive mechanical ventilation, the incidence of acute organ injury, and ICU and hospital length of stay, were generally similar between pregnant and nonpregnant women. Pregnant women had high rates of preterm delivery and cesarean section—primarily for the indication of critical illness. Our finding that 13 pregnant women survived to hospital discharge without delivery raises an interesting question of whether or not delivery is required for nonobstetric indications among critically ill pregnant women (10). Additional data are needed in critically ill pregnant women with COVID-19 to help inform clinical practice.

Author disclosures are available with the text of this letter at www.atlsjournals.org.

Sarah Rae Easter, M.D.∗ Shruti Gupta, M.D., M.P.H.
Brigham and Women’s Hospital
Boston, Massachusetts
and
Harvard Medical School
Boston, Massachusetts

Samantha K. Brenner, M.D., M.P.H.
Hackensack Meridian School of Medicine
Nutley, New Jersey
and
Hackensack Meridian Health Hackensack University Medical Center
Hackensack, New Jersey

David E. Leaf, M.D., M.M.Sc.
Brigham and Women’s Hospital
Boston, Massachusetts
and
Harvard Medical School
Boston, Massachusetts

ORCID IDs: 0000-0002-0150-3537 (S.R.E.); 0000-0002-5747-2151 (S.G.);
0000-0001-7875-090X (D.E.L.).

∗Corresponding author (e-mail: seaster@bwh.harvard.edu).

What Sepsis Researchers Can Learn from COVID-19

To the Editor:

Despite intensive research efforts, the search for new therapeutic options for sepsis has yielded no result (1). However, the ongoing coronavirus disease (COVID-19) pandemic shows that effective therapeutic options for the distinct subgroup of viral sepsis due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can be found within months (2). What can sepsis researchers learn from the way COVID-19 is studied?

Heterogeneity

In clinical practice, recognition of the wider sepsis syndrome can improve awareness and timely initiation of treatment. However, when looking for new therapeutic options in a research setting, this broad approach may be less desirable. One of the questionable tenets of sepsis research has been whether the host response in sepsis represents a “final common pathway” irrespective of the source of infection or causative pathogens (1). This would justify looking at the broader sepsis population in research, with the added benefit of having larger study cohorts. However, most believe that the host response is just too complex and that a “final common pathway” may simply not exist (1). The resultant heterogeneity within the sepsis population is therefore considered to be a major limiting factor in finding specific sepsis therapies (1, 3). Extensive efforts have thus been made to reveal homogeneous sepsis subgroups (1, 3, 4). Shared and distinct gene expression profiles are found when pulmonary and abdominal sepsis are compared (3), suggesting that part of the heterogeneity in the sepsis population could be explained by the infection site or invading pathogen. Several other studies that aim to find homogeneous sepsis subgroups through systematic review have been unsuccessful (3–7).

In summary, we report the maternal and fetal outcomes of 32 pregnant women in a multicenter cohort study of geographically diverse critically ill patients with COVID-19. In contrast to nonpregnant women of childbearing age, all pregnant women survived, and there were no fetal deaths. Treatments and outcomes, including receipt of invasive mechanical ventilation, the incidence of acute organ injury, and ICU and hospital length of stay, were generally similar between pregnant and nonpregnant women. Pregnant women had high rates of preterm delivery and cesarean section—primarily for the indication of critical illness. Our finding that 13 pregnant women survived to hospital discharge without delivery raises an interesting question of whether or not delivery is required for nonobstetric indications among critically ill pregnant women (10). Additional data are needed in critically ill pregnant women with COVID-19 to help inform clinical practice.

Author disclosures are available with the text of this letter at www.atlsjournals.org.

Sarah Rae Easter, M.D.∗ Shruti Gupta, M.D., M.P.H.
Brigham and Women’s Hospital
Boston, Massachusetts
and
Harvard Medical School
Boston, Massachusetts

Samantha K. Brenner, M.D., M.P.H.
Hackensack Meridian School of Medicine
Nutley, New Jersey
and
Hackensack Meridian Health Hackensack University Medical Center
Hackensack, New Jersey

David E. Leaf, M.D., M.M.Sc.
Brigham and Women’s Hospital
Boston, Massachusetts
and
Harvard Medical School
Boston, Massachusetts

ORCID IDs: 0000-0002-0150-3537 (S.R.E.); 0000-0002-5747-2151 (S.G.);
0000-0001-7875-090X (D.E.L.).

∗Corresponding author (e-mail: seaster@bwh.harvard.edu).

What Sepsis Researchers Can Learn from COVID-19

To the Editor:

Despite intensive research efforts, the search for new therapeutic options for sepsis has yielded no result (1). However, the ongoing coronavirus disease (COVID-19) pandemic shows that effective therapeutic options for the distinct subgroup of viral sepsis due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can be found within months (2). What can sepsis researchers learn from the way COVID-19 is studied?

Heterogeneity

In clinical practice, recognition of the wider sepsis syndrome can improve awareness and timely initiation of treatment. However, when looking for new therapeutic options in a research setting, this broad approach may be less desirable. One of the questionable tenets of sepsis research has been whether the host response in sepsis represents a “final common pathway” irrespective of the source of infection or causative pathogens (1). This would justify looking at the broader sepsis population in research, with the added benefit of having larger study cohorts. However, most believe that the host response is just too complex and that a “final common pathway” may simply not exist (1). The resultant heterogeneity within the sepsis population is therefore considered to be a major limiting factor in finding specific sepsis therapies (1, 3). Extensive efforts have thus been made to reveal homogeneous sepsis subgroups (1, 3, 4).

Shared and distinct gene expression profiles are found when pulmonary and abdominal sepsis are compared (3), suggesting that part of the heterogeneity in the sepsis population could be explained by the infection site or invading pathogen. Several other studies that aim to find homogeneous sepsis subgroups through